Dynavax received U.S. FDA nod for Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]

Hepatitis B Vaccine

Dynavax received U.S. FDA nod for Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]

 

U.S. FDA approved Dynavax drugs Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] for the treatment of Hepatitis B.

Company: Dynavax

Specific Treatments: Hepatitis B virus

Therapeutic Areas: Hepatology (Gall Bladder, Pancreatic, Liver), Infections and Infectious Diseases

 

 

General Information of Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]

Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.

 

Heplisav-B is specifically indicated for prevention of infection caused by all known subtypes of hepatitis B virus for use in adults 18 years of age and older. 

 

Heplisav-B is supplied as a solution for intramuscular injection. The recommended dose is two doses (0.5 mL each) administered one month apart.

 

Our App

Scan QR Code To Add On WeChat

Connect on WeChat

Contact Us

Address : 4216/20, Ground Floor, 1 Ansari Road, Daryaganj, New Delhi - 110002 (India)

[email protected]

QQ : [email protected]

Phone : +91-11-43526658

Mobile : +91-9873336444

Skype : Oddway2010

WeChat : Oddway2010

WhatsApp : +91-9873336444

Viber : +91-9873336444

Telegram : +91-9873336444

Signal : +91-9873336444